1193162-21-8

Basic information

• Product Name: Methyl 4-broMo-2,5-difluorobenzoate
• Synonyms: Methyl 4-broMo-2,5-difluorobenzoate;methy 4-bromo-2,5-difluorobenzoate;4-Bromo-2,5-difluoro-benzoic acid methyl ester
• CAS NO: 1193162-21-8
• Molecular Formula: C8H5BrF2O2
• Molecular Weight: 251.0249064
• EINECS: -0
• Mol File: 1193162-21-8.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 4-broMo-2,5-difluorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-broMo-2,5-difluorobenzoate(1193162-21-8)
• EPA Substance Registry System: Methyl 4-broMo-2,5-difluorobenzoate(1193162-21-8)

Safety Data

• Hazardous Substances Data: 1193162-21-8(Hazardous Substances Data)

Usage

General Description

Methyl 4-bromo-2,5-difluorobenzoate is a chemical compound that belongs to the ester class of organic compounds. It is a brominated benzoate ester with two fluorine atoms attached to the benzene ring. Methyl 4-broMo-2,5-difluorobenzoate is commonly used in chemical and pharmaceutical research as a building block or intermediate for the synthesis of various organic compounds. It is also used as a reagent in organic synthesis and as a starting material for the preparation of pharmaceuticals and agrochemicals. The presence of bromine and fluorine in the compound makes it useful for the development of new drugs and agricultural products. Overall, Methyl 4-bromo-2,5-difluorobenzoate is an important chemical compound with various applications in the chemical and pharmaceutical industries.

Upstream product

• 186581-53-3 diazomethane 
• 28314-82-1 4-bromo-2,5-difluorobenzoic acid 
• 327-51-5 1,4-dibromo-2,5-difluorobenzene 
• 67-56-1 methanol 

Downstream Products

• 764648-42-2 4-bromo-2,5-difluorobenzamide 

Relevant articles and documents

Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens

A series of conformationally constrained novel benzo[1,3]oxazinyloxazolidinones were designed, synthesized, and evaluated on their activities against Mycobacterium tuberculosis, Gram-positive bacteria, and Gram-negative bacteria. The studies identified a new compound 20aa that displayed good to excellent antibacterial and antitubercular profiles against drug-resistant TB strains (MIC = 0.48-0.82 μg/mL), MRSA (MIC = 0.25-0.5 μg/mL), MRSE (MIC = 1 μg/mL), VISA (MIC = 0.25 μg/mL), and VRE (MIC = 0.25 μg/mL) and some linezolid-resistant strains (MIC 1-2 μg/mL). Compound 20aa was demonstrated as a promising candidate through ADME/T evaluation including microsomal stability, cytotoxicity, and inhibition of hERG and monoamine oxidase. Notably, 20aa showed excellent mouse PK profile with high plasma exposure (AUC0-∞ = 78 669 h·ng/mL), high peak plasma concentration (Cmax = 10 253 ng/mL), appropriate half-life of 3.76 h, and superior oral bioavailability (128%). The present study not only successfully provides a novel benzo[1,3]oxazinyloxazolidinone scaffold with superior druggability but also lays a good foundation for new antibacterial drug development.

SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF

Provided is a sulfonamide derivative represented by the following general formula (1) and having an α4 integrin inhibitory effect with high selectivity with a low effect on α4β1 and a high effect on α4β7, or a pharmaceutically acceptable salt thereof (in the general formula (1), A, B, D, E, R41, and a to h are as described in the description).

SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF

Provided are sulfonamide derivatives of a specific chemical structure in which a sulfonamide group having, as a substituent, a phenyl group or a heterocyclic group having a hetero atom(s) as a constituent element(s) is present at its terminal, and pharmaceutically acceptable salts thereof. These compounds are novel compounds having excellent α4 integrin-inhibitory action.